UK: Brexit And Life Sciences Update

Last Updated: 24 August 2018
Article by Nina O'Sullivan

We last reported on Brexit developments in the May 2018 edition where we focused on the resounding message that the industry still had to prepare for a hard Brexit, whilst hoping for an agreement incorporating an implementation period to allow breathing room to adjust to the post-Brexit position, and for bespoke arrangements to be made on certain key issues. These could include perhaps the UK's continued membership of the EMA, with a majority of MPs voting in July that the UK should negotiate for this. As we approach the October deadline for an agreed position on the draft withdrawal agreement, a number of important statements and reports have been issued.

MHRA Statements

In early August, the MHRA issued a series of statements intended to allay the fears of industry in relation to certain aspects. However, the statements are all premised on the basis that an agreement will be reached which includes the implementation period until the end of 2020. By failing to deal with the steps needed to prepare for a no deal Brexit, it is questionable how reassuring these statements will be.

The MHRA's statements cover the following topics:

Impact of the implementation period for the sector

Assuming an implementation period is agreed, it will remain business as usual in relation to the following aspects during that period:

  • Batch testing and Qualified Person certification can continue in the UK.
  • Marketing authorisation holders and qualified persons for pharmacovigilance will still be able  to be based in the UK and access EU markets.
  • UK-based firms will continue to be able to apply for marketing authorisations using either the centralised or decentralised procedures.
  • CE marking for medical devices will continue to be used and recognised for both markets and UK-based firms and they will not need an authorised representative established in the EU. UK notified bodies will also continue to conduct third party conformity assessment in the UK.

The statement also notes the agreement reached in March that the UK will be treated as a Member State for the purposes of international agreements, including Mutual Recognition Agreements, during the implementation period.

However, and significantly, during the implementation period, the UK will effectively be a 'rule-taker', with no voting rights in the EMA and EU committees.

Impact on forthcoming EU Regulation

The new Clinical Trials Regulation is anticipated to be implemented during 2020, i.e., before the end of the proposed implementation period. However, if it is not implemented in time, the Government has confirmed that UK law will 'remain aligned with parts of the EU's CTR legislation that are within the UK's control'. Of course, there are two significant elements that the UK could not implement without the EU's agreement: use of the shared central portal and participation in the single assessment model.

The MHRA statement also confirms that, if the UK is outside the EU network after the implementation period, sponsors will still be able to run multi-state trials involving the UK. Whilst they will need to apply to the MHRA separately, it 'would take every effort to ensure this parallel submission is as streamlined and efficient as possible'.

The Medical Devices Regulation will apply fully from May 2020, which again falls during the proposed implementation period. However, the In Vitro Diagnostic (IVD) Regulation does not apply until May 2022, although the statement notes that elements of both new devices Regulations have been applying directly in the UK since May 2017, thereby allowing medical devices (including IVDs) to be placed on the UK market if in conformity with the new regulations.

Cancer Research Report

The MHRA statements were published in the same week as a report commissioned by Cancer Research UK (conducted by School of International Futures) as to the priorities during the negotiations and the future of clinical trials post Brexit (both short term and long term). The significance of this issue cannot be over-stated with 823 applications for commercial clinical trials of medicines having been submitted in the UK in 2017.

Proposals in the report include:

  • Full alignment with the EU clinical trials regime, and a bespoke agreement for access to the EU portal and database (as noted above, this is the MHRA's priority also).
  • Continued access to medicines, Investigational Medicinal Products (IMPs) and medical devices (i.e., no trade barriers impacting on the movement of such products and on clinical trials).
  • Funding initiatives for clinical trials should be a priority for the Government.
  • Ensuring the right talent through a permissive immigration system and investment in a skilled clinical trials workforce.

EMA

In the meantime, Brexit has had a significant impact on the operations of the EMA. The next phase of its business continuity plan (to be launched on 1 October 2018) will involve a temporary scaling back and suspension of activities, in order to safeguard core activities relating to evaluation and supervision of medicines. This has been caused by the 'significant staff loss' caused by the move to Amsterdam in March 2019, which the EMA admits is more than initially anticipated, with staff members already starting to leave. The EMA expects a staff loss of around 30%.

It has also published the results of its Brexit preparedness survey of UK based marketing authorisation holders (or those MA holders with an important step in their regulatory processes in the UK) for centrally authorised products. Whilst the results of the survey indicated preparations had started, the EMA is concerned that, for some medicines, these procedures will not be implemented in time to allow continued supply post-March 2019, and also that many businesses are planning to take the necessary steps in Q1 of 2019, during the peak period for relocation of the EMA.

Next steps

Developments to look for in the coming weeks, aside from the October deadline, include the long-awaited full report by the Migration Advisory Committee into EEA workers in the UK market due in September 2018. We also await news of the EY study commissioned to assess the impact of Brexit on cross-border medicinal supplies.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Arnold & Porter
Reed Smith (Worldwide)
Bird & Bird
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Arnold & Porter
Reed Smith (Worldwide)
Bird & Bird
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions